Zhou Yongji, Chen Yanxing, Xu Congcong, Zhang Hao, Lin Caixiu
Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Neurosci. 2020 Dec 18;14:602508. doi: 10.3389/fnins.2020.602508. eCollection 2020.
Alzheimer disease (AD) is a devastating neurodegenerative disorder characterized by extracellular accumulation of amyloid-beta and formation of intracellular neurofibrillary tangles. Microglia activation and neuroinflammation play important roles in the pathogenesis of AD; Toll-like receptor 4 (TLR4)-a key component of the innate immune system-in microglia is also thought to be involved based on the observed association between TLR gene polymorphisms and AD risk. TLR4 has been shown to exert both detrimental and beneficial effects on AD-related pathologies. In preclinical models, experimental manipulations targeting TLR4 were shown to improve learning and memory, which was related to inhibition of pro-inflammatory cytokine release and reduction of oxidative stress. In this review, we summarize the key evidence supporting TLR4 as a promising therapeutic target in AD treatment.
阿尔茨海默病(AD)是一种毁灭性的神经退行性疾病,其特征是细胞外β淀粉样蛋白的积累和细胞内神经原纤维缠结的形成。小胶质细胞激活和神经炎症在AD的发病机制中起重要作用;基于观察到的Toll样受体(TLR)基因多态性与AD风险之间的关联,小胶质细胞中先天免疫系统的关键组成部分Toll样受体4(TLR4)也被认为与之有关。TLR4已被证明对AD相关病理具有有害和有益的影响。在临床前模型中,针对TLR4的实验操作显示可改善学习和记忆,这与抑制促炎细胞因子释放和降低氧化应激有关。在这篇综述中,我们总结了支持TLR4作为AD治疗中有前景的治疗靶点的关键证据。